Back to results
US 2025/0352619 A1Published application
Recombinant hsv-1 vector for encoding immunostimulatory factor and anti-immune checkpoint antibody
AssigneesWuxi Apptec (Shanghai) Co., Ltd., Shanghai Ark Biopharmaceutical Co., Ltd.
InventorsJunmei ZHANG, Wei MA, Jim Zhen WU, Gang ZOU, Zhao GAO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a modified HSV-1 vector. The HSV-1 vector comprises an exogenous nucleotide sequence encoding an immunostimulatory factor and/or an anti-immune checkpoint antibody. The HSV-1 vector of the present disclosure can be used for treating cancers.
Claims20
A recombinant HSV-1 vector comprising a modified HSV-1 genome, wherein the modification comprises a deletion of the ICP34.5 gene in a HSV1-KOS strain genome, and the recombinant HSV-1 vector comprises:
- (a) a first exogenous nucleic acid sequence encoding an immunostimulatory factor;
- and (b) a second exogenous nucleic acid sequence encoding an anti-immune checkpoint antibody;
- wherein an insertion site of the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence is between the UL26 and UL27 genes of the HSV1-KOS strain genome, and the insertion of the first exogenous nucleic acid sequence or the second exogenous nucleic acid sequence does not interfere with an expression of HSV-1.
Dependencies are inferred from the claim text.